- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1616KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 875KB)
Acalabrutinib – November 2021
Acalabrutinib: Capsule 100 mg; Calquence®
Last updated
17 February 2023